1. Home
  2. AZTA vs XERS Comparison

AZTA vs XERS Comparison

Compare AZTA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Azenta Inc.

AZTA

Azenta Inc.

SELL

Current Price

$34.09

Market Cap

1.7B

Sector

Technology

ML Signal

SELL

XERS

Xeris Biopharma Holdings Inc.

SELL

Current Price

$10.31

Market Cap

1.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AZTA
XERS
Founded
1978
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
AZTA
XERS
Price
$34.09
$10.31
Analyst Decision
Buy
Strong Buy
Analyst Count
6
7
Target Price
★ $39.00
$12.86
AVG Volume (30 Days)
1.0M
★ 2.4M
Earning Date
11-20-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 100.00
EPS
N/A
★ N/A
Revenue
★ $593,821,000.00
$49,590,000.00
Revenue This Year
$3.54
$32.91
Revenue Next Year
$3.89
$23.75
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 142.67
52 Week Low
$15.93
$5.25
52 Week High
$46.41
$10.60

Technical Indicators

Market Signals
Indicator
AZTA
XERS
Relative Strength Index (RSI) 43.99 61.52
Support Level $31.86 $5.90
Resistance Level $37.49 $10.60
Average True Range (ATR) 2.36 0.47
MACD -0.36 0.00
Stochastic Oscillator 3.89 74.12

Price Performance

Historical Comparison
AZTA
XERS

About AZTA Azenta Inc.

Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: